COMPOUND PROFILE / SMALL MOLECULES
Azelaprag / BGE-105.
Research draftAzelaprag, also called BGE-105, is an experimental small-molecule apelin-receptor agonist.
Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.
Targeted source and identity review, not a systematic review or complete regulatory audit.
Overview
Azelaprag, also called BGE-105, is an experimental small-molecule apelin-receptor agonist.
Mechanism
It targets apelin signalling implicated in muscle and metabolic physiology.
Human research
Human development occurred, but the STRIDES combination trial was discontinued after liver-enzyme elevations.
Preclinical & other research
Cell and animal research investigated muscle and metabolic effects.
Safety & unknowns
The liver-safety signal is material and should remain visible alongside efficacy claims.
Regulatory status
Discontinued trial status is documented by the developer; current programme status needs a separate check.
Reported use & evidence
The supplied Azelaprag / BGE-105 profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.
Sources & references
Follow the cited records and registered research. Profiles remain research drafts.